Enveric Biosciences Reports First Quarter 2026 Results and Advances Non-Hallucinogenic Neuroplastogen Pipeline
Enveric Biosciences reported financial results for the first quarter ended March 31, 2026, while also providing an extensive business update highlighting continued progress in the development of its lead neuroplastogenic drug candidate, EB-003. The company emphasized advancements across preclinical research, intellectual property expansion, financing activities, and strategic partnerships as it works toward transitioning into clinical-stage development.
Enveric Biosciences is focused on developing next-generation neuroplastogenic small molecules intended to treat psychiatric and neurological disorders. The company’s research strategy centers on designing compounds inspired by psychedelic mechanisms while eliminating the hallucinogenic effects that have historically limited broader therapeutic adoption of psychedelic-based treatments.
According to Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences, the company’s first-quarter achievements demonstrate continued execution against its long-term mission of addressing major unmet needs in mental health care through innovative neuroscience therapies.
Tucker stated that Enveric remains highly focused on advancing EB-003, the company’s lead development candidate, toward an Investigational New Drug application submission and eventual first-in-human clinical studies. He explained that the company believes EB-003 represents a differentiated approach within the emerging neuroplastogen field because it seeks to preserve the therapeutic advantages associated with psychedelic-inspired pathways without inducing hallucinations or perceptual disturbances.
The company believes this non-hallucinogenic profile could significantly improve the scalability, accessibility, safety, and practicality of future psychiatric treatments. Traditional psychedelic therapies often require extensive clinical monitoring and supervised treatment environments due to their psychoactive effects, creating operational and logistical challenges for large-scale patient use. Enveric’s strategy aims to overcome those limitations while still promoting the neuroplastic changes believed to underlie therapeutic benefit.
Tucker noted that the company’s expanding body of preclinical evidence continues to support the therapeutic potential of EB-003. According to Enveric, recent studies indicate that the compound promotes neuroplasticity through selective receptor engagement mechanisms associated with antidepressant and anxiolytic activity.
One of the key scientific updates during the quarter involved the release of receptor engagement assay data for EB-003. The company reported findings from BRET-based assays showing dual Gq and β-arrestin signaling activity at the 5-HT2A receptor. These signaling pathways have been linked in peer-reviewed scientific literature to antidepressant and anti-anxiety effects.
The 5-HT2A receptor is widely recognized as a critical target in psychedelic and neuroplastogenic drug development. However, many existing compounds targeting this receptor produce hallucinogenic experiences that may limit widespread clinical use. Enveric’s approach seeks to selectively engage therapeutic signaling pathways while minimizing or eliminating hallucinogenic effects.
The company believes these receptor signaling findings further validate its medicinal chemistry platform and support the continued advancement of EB-003 as a potentially rapid-acting neuropsychiatric therapy.
Subsequent to the close of the first quarter, Enveric also announced additional positive preclinical findings related to EB-003 in a validated model of post-traumatic stress disorder. According to the company, the compound demonstrated a rapid reduction in conditioned fear response, a key behavioral measure frequently used in PTSD-related research.
Management indicated that these results strengthen the rationale for exploring EB-003 in PTSD and other psychiatric conditions characterized by maladaptive fear responses, anxiety, and impaired emotional processing. The company believes the growing preclinical dataset supports the possibility that EB-003 could provide durable therapeutic benefits across multiple neuropsychiatric indications.
In addition to pipeline development, Enveric highlighted several achievements related to its intellectual property portfolio, which the company views as a major strategic asset supporting long-term value creation.
One of the most notable developments involved the withdrawal of a Post-Grant Review petition that had been filed by Gilgamesh Pharmaceuticals concerning patents believed to be relevant to the bretisilocin molecule, also known as GM-2505. Bretisilocin became a high-profile asset after its acquisition by AbbVie through a deal valued at approximately $1.2 billion.
Enveric stated that the withdrawal of the petition reinforces the perceived strength, breadth, and strategic importance of its intellectual property portfolio. The company believes its patent estate not only protects its own innovation pipeline but may also support future licensing, collaboration, and monetization opportunities within the broader neuroplastogen and psychedelic-inspired therapeutics market.
During the quarter, Enveric also expanded the intellectual property coverage surrounding its EVM301 portfolio, which includes non-hallucinogenic tryptamine derivative molecules intended for neuropsychiatric applications. According to the company, these additions enhance claim coverage around N-heterocycle substituted tryptamine compounds designed for treating psychiatric and neurological conditions.
The company further strengthened its corporate branding strategy by securing registration for five trademarks through the Canadian Intellectual Property Office. These registrations included the company’s core house marks, “Enveric” and “Enveric Biosciences.”
Beyond research and intellectual property initiatives, Enveric also executed several financing and business development transactions aimed at strengthening its operational runway and supporting continued development activities.
During the first quarter of 2026, the company raised approximately $1.5 million in gross proceeds through a registered direct offering priced at-the-market under Nasdaq rules. Enveric also expanded its collaboration with TOTEC Pharma through a trademark license and option agreement involving the out-licensing of the RCANN trademark portfolio.
Subsequent to quarter-end, Enveric completed additional financing activities that further enhanced its cash position. The company raised approximately another $1.5 million through the exercise of Series G and H warrants at an exercise price of $4.16 per share.
In April 2026, Enveric also completed a private placement transaction expected to generate gross proceeds of up to $13.9 million. The financing included $5 million received upfront at closing, with the potential for approximately $8.9 million in additional proceeds if all associated warrants are exercised in full.
Management indicated that the capital raised through these transactions is expected to support ongoing preclinical development activities for EB-003, preparation for IND submission, and general corporate operations into the first quarter of fiscal year 2027.
Kevin Coveney, CPA, Chief Financial Officer of Enveric Biosciences, stated that the company’s strengthened balance sheet provides increased financial flexibility as it approaches key development milestones. Coveney noted that, as of May 15, 2026, Enveric’s cash balance stood at approximately $10.3 million.
The company reported a net loss attributable to stockholders of $1.6 million for the first quarter ended March 31, 2026. This included approximately $0.1 million in net non-cash expense. On a per-share basis, Enveric recorded a basic and diluted net loss of $1.08 per share.
This compares favorably with the first quarter of 2025, during which the company reported a net loss of $2.2 million, including approximately $0.3 million in net non-cash income, and a basic and diluted loss per share of $14.58.
Enveric reported cash-on-hand totaling $4.9 million at the end of the first quarter of 2026. During the quarter, the company raised total gross proceeds of approximately $2.8 million through financing activities.
The broader mental health treatment landscape continues to evolve rapidly, with increasing scientific, regulatory, and public interest in psychedelic-inspired therapeutics and neuroplasticity-based treatment approaches. Enveric noted that recent policy developments appear to signal growing institutional support for innovation in mental health therapies.
Tucker referenced recent actions under President Donald Trump’s administration, including an Executive Order emphasizing the importance of advancing novel treatments for mental health conditions. According to Tucker, these developments underscore increasing recognition of the therapeutic promise associated with psychedelic-inspired mechanisms.
However, Enveric maintains that the future of the field may ultimately be defined by non-hallucinogenic neuroplastogens capable of delivering therapeutic benefits without the operational limitations associated with traditional psychedelics.
As the company advances toward clinical-stage development, management believes Enveric is increasingly well positioned within the emerging neuroplastogen sector. With IND-enabling studies underway, expanding intellectual property protections, additional financing secured, and growing preclinical validation for EB-003, the company is preparing for what it views as the next major phase of its development strategy.
Looking ahead, Enveric plans to continue advancing EB-003 through preclinical development while preparing regulatory submissions necessary to initiate first-in-human clinical trials. The company also intends to further expand its intellectual property estate and explore additional opportunities to leverage its neuroscience platform in psychiatric and neurological disorders characterized by substantial unmet medical need.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
